These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
189 related articles for article (PubMed ID: 21464249)
1. Plasma and intracellular tenofovir pharmacokinetics in the neonate (ANRS 12109 trial, step 2). Hirt D; Ekouévi DK; Pruvost A; Urien S; Arrivé E; Blanche S; Avit D; Amani-Bosse C; Nyati M; Legote S; Ek ML; Say L; McIntyre J; Dabis F; Tréluyer JM Antimicrob Agents Chemother; 2011 Jun; 55(6):2961-7. PubMed ID: 21464249 [TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and safety of single-dose tenofovir disoproxil fumarate and emtricitabine in HIV-1-infected pregnant women and their infants. Flynn PM; Mirochnick M; Shapiro DE; Bardeguez A; Rodman J; Robbins B; Huang S; Fiscus SA; Van Rompay KK; Rooney JF; Kearney B; Mofenson LM; Watts DH; Jean-Philippe P; Heckman B; Thorpe E; Cotter A; Purswani M; Antimicrob Agents Chemother; 2011 Dec; 55(12):5914-22. PubMed ID: 21896911 [TBL] [Abstract][Full Text] [Related]
3. Very high concentrations of active intracellular phosphorylated emtricitabine in neonates (ANRS 12109 trial, step 2). Hirt D; Pruvost A; Ekouévi DK; Urien S; Arrivé E; Kone M; Nerrienet E; Nyati M; Gray G; Kruy LS; Blanche S; Dabis F; Tréluyer JM Antimicrob Agents Chemother; 2011 Jun; 55(6):2953-60. PubMed ID: 21464241 [TBL] [Abstract][Full Text] [Related]
4. Tenofovir, emtricitabine, and tenofovir diphosphate in dried blood spots for determining recent and cumulative drug exposure. Castillo-Mancilla JR; Zheng JH; Rower JE; Meditz A; Gardner EM; Predhomme J; Fernandez C; Langness J; Kiser JJ; Bushman LR; Anderson PL AIDS Res Hum Retroviruses; 2013 Feb; 29(2):384-90. PubMed ID: 22935078 [TBL] [Abstract][Full Text] [Related]
5. Tenofovir diphosphate and emtricitabine triphosphate concentrations in blood cells compared with isolated peripheral blood mononuclear cells: a new measure of antiretroviral adherence? Adams JL; Sykes C; Menezes P; Prince HM; Patterson KB; Fransen K; Crucitti T; De Baetselier I; Van Damme L; Kashuba AD J Acquir Immune Defic Syndr; 2013 Mar; 62(3):260-6. PubMed ID: 23111578 [TBL] [Abstract][Full Text] [Related]
6. Single dose pharmacokinetics of oral tenofovir in plasma, peripheral blood mononuclear cells, colonic tissue, and vaginal tissue. Louissaint NA; Cao YJ; Skipper PL; Liberman RG; Tannenbaum SR; Nimmagadda S; Anderson JR; Everts S; Bakshi R; Fuchs EJ; Hendrix CW AIDS Res Hum Retroviruses; 2013 Nov; 29(11):1443-50. PubMed ID: 23600365 [TBL] [Abstract][Full Text] [Related]
7. Age-related differences in plasma and intracellular tenofovir concentrations in HIV-1-infected children, adolescents and adults. Baheti G; King JR; Acosta EP; Fletcher CV AIDS; 2013 Jan; 27(2):221-5. PubMed ID: 23032419 [TBL] [Abstract][Full Text] [Related]
8. Plasma and intracellular pharmacokinetics of tenofovir in patients switched from tenofovir disoproxil fumarate to tenofovir alafenamide. Podany AT; Bares SH; Havens J; Dyavar SR; O'Neill J; Lee S; Fletcher CV; Swindells S; Scarsi KK AIDS; 2018 Mar; 32(6):761-765. PubMed ID: 29334548 [TBL] [Abstract][Full Text] [Related]
9. Population pharmacokinetics of emtricitabine in human immunodeficiency virus type 1-infected pregnant women and their neonates. Hirt D; Urien S; Rey E; Arrivé E; Ekouévi DK; Coffié P; Leang SK; Lalsab S; Avit D; Nerrienet E; McIntyre J; Blanche S; Dabis F; Tréluyer JM Antimicrob Agents Chemother; 2009 Mar; 53(3):1067-73. PubMed ID: 19104016 [TBL] [Abstract][Full Text] [Related]
10. Penetration of tenofovir and emtricitabine in mucosal tissues: implications for prevention of HIV-1 transmission. Patterson KB; Prince HA; Kraft E; Jenkins AJ; Shaheen NJ; Rooney JF; Cohen MS; Kashuba AD Sci Transl Med; 2011 Dec; 3(112):112re4. PubMed ID: 22158861 [TBL] [Abstract][Full Text] [Related]
11. Tenofovir, emtricitabine intracellular and plasma, and efavirenz plasma concentration decay following drug intake cessation: implications for HIV treatment and prevention. Jackson A; Moyle G; Watson V; Tjia J; Ammara A; Back D; Mohabeer M; Gazzard B; Boffito M J Acquir Immune Defic Syndr; 2013 Mar; 62(3):275-81. PubMed ID: 23274933 [TBL] [Abstract][Full Text] [Related]
12. Dose Frequency Ranging Pharmacokinetic Study of Tenofovir-Emtricitabine After Directly Observed Dosing in Healthy Volunteers to Establish Adherence Benchmarks (HPTN 066). Hendrix CW; Andrade A; Bumpus NN; Kashuba AD; Marzinke MA; Moore A; Anderson PL; Bushman LR; Fuchs EJ; Wiggins I; Radebaugh C; Prince HA; Bakshi RP; Wang R; Richardson P; Shieh E; McKinstry L; Li X; Donnell D; Elharrar V; Mayer KH; Patterson KB AIDS Res Hum Retroviruses; 2016 Jan; 32(1):32-43. PubMed ID: 26414912 [TBL] [Abstract][Full Text] [Related]
13. Pilot pharmacokinetic study of human immunodeficiency virus-infected patients receiving tenofovir disoproxil fumarate (TDF): investigation of systemic and intracellular interactions between TDF and abacavir, lamivudine, or lopinavir-ritonavir. Pruvost A; Negredo E; Théodoro F; Puig J; Levi M; Ayen R; Grassi J; Clotet B Antimicrob Agents Chemother; 2009 May; 53(5):1937-43. PubMed ID: 19273671 [TBL] [Abstract][Full Text] [Related]
14. Antenatal Intracellular Concentrations of Tenofovir Diphosphate and Emtricitabine Triphosphate and Associations Between Tenofovir Diphosphate and Severe Adverse Pregnancy Outcomes: IMPAACT-PROMISE (1077BF) Trial. Aizire J; Brooks KM; Mirochnick M; Flynn PM; Butler K; Kiser JJ; Siberry GK; Fenton T; Cababasay M; Fowler MG; J Acquir Immune Defic Syndr; 2020 Feb; 83(2):173-180. PubMed ID: 31929405 [TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of antiretroviral regimens containing tenofovir disoproxil fumarate and atazanavir-ritonavir in adolescents and young adults with human immunodeficiency virus infection. Kiser JJ; Fletcher CV; Flynn PM; Cunningham CK; Wilson CM; Kapogiannis BG; Major-Wilson H; Viani RM; Liu NX; Muenz LR; Harris DR; Havens PL; Antimicrob Agents Chemother; 2008 Feb; 52(2):631-7. PubMed ID: 18025112 [TBL] [Abstract][Full Text] [Related]
16. Plasma and intracellular population pharmacokinetic analysis of tenofovir in HIV-1-infected patients. Baheti G; Kiser JJ; Havens PL; Fletcher CV Antimicrob Agents Chemother; 2011 Nov; 55(11):5294-9. PubMed ID: 21896913 [TBL] [Abstract][Full Text] [Related]
17. Effect of Pregnancy and Concomitant Antiretrovirals on the Pharmacokinetics of Tenofovir in Women With HIV Receiving Tenofovir Disoproxil Fumarate-Based Antiretroviral Therapy Versus Women With HBV Receiving Tenofovir Disoproxil Fumarate Monotherapy. Bukkems VE; Smolders EJ; Jourdain G; Burger DM; Colbers AP; Cressey TR; J Clin Pharmacol; 2021 Mar; 61(3):388-393. PubMed ID: 32960984 [TBL] [Abstract][Full Text] [Related]
18. Natural substrate concentrations can modulate the prophylactic efficacy of nucleotide HIV reverse transcriptase inhibitors. García-Lerma JG; Aung W; Cong ME; Zheng Q; Youngpairoj AS; Mitchell J; Holder A; Martin A; Kuklenyik S; Luo W; Lin CY; Hanson DL; Kersh E; Pau CP; Ray AS; Rooney JF; Lee WA; Heneine W J Virol; 2011 Jul; 85(13):6610-7. PubMed ID: 21525346 [TBL] [Abstract][Full Text] [Related]
19. Intracellular nucleotide levels during coadministration of tenofovir disoproxil fumarate and didanosine in HIV-1-infected patients. Hawkins T; Veikley W; Durand-Gasselin L; Babusis D; Reddy YS; Flaherty JF; Ray AS Antimicrob Agents Chemother; 2011 Apr; 55(4):1549-55. PubMed ID: 21282432 [TBL] [Abstract][Full Text] [Related]
20. Model Linking Plasma and Intracellular Tenofovir/Emtricitabine with Deoxynucleoside Triphosphates. Chen X; Seifert SM; Castillo-Mancilla JR; Bushman LR; Zheng JH; Kiser JJ; MaWhinney S; Anderson PL PLoS One; 2016; 11(11):e0165505. PubMed ID: 27832147 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]